+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study



Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study



Drugs and Aging 30(11): 927-934



Older people are exposed to multiple medicines that possess anticholinergic properties. The use of anticholinergic medicines is associated with the risk of morbidity, mortality and cognitive decline, particularly in older people. Anticholinergic exposure can be measured using tools such as the Drug Burden Index-Anticholinergic component (DBI-ACh) and the Anticholinergic Drug Scale (ADS). The aim of this population-level study was to determine the extent of anticholinergic exposure in older people, particularly among those receiving acetylcholinesterase inhibitors in New Zealand. The study used data extracted from Pharmaceutical Claims Data Mart (Pharms) for the year 2011. A total of 537,387 individuals aged 65 years and older were included in the study, of whom 45.10 % were men. Individuals dispensed donepezil at any time during 2011 were selected as the acetylcholinesterase inhibitor (AChEI) group (n = 4,258) and the remainder were included in the non-acetylcholinesterase inhibitor (non-AChEI) group (n = 533,129). Anticholinergic exposure was measured using the DBI-ACh and the ADS. Analysis of the Pharms dataset revealed that, in 2011, anticholinergic exposure as defined by the DBI-ACh and the ADS was 31.80 % and 52.66 %, respectively. The mean number of medicines dispensed was 5.64 ± 3.91 (± SD) with a 95 % confidence interval of 5.63-5.65. In the AChEI group, anticholinergic exposure using the DBI-ACh and the ADS was 42.93 % (median 0; interquartile range (IQR) 1) and 58.50 % (median 0; IQR 0), respectively. ADS level 3 medicines such as amitriptyline, nortriptyline and oxybutynin were commonly prescribed in both groups. Amitriptyline, nortriptyline, oxybutynin and paroxetine are medicines considered to have significant anticholinergic potency. Of these medicines, nortriptyline and oxybutynin were more frequently prescribed in individuals taking donepezil. A significant proportion of older people are exposed to medicines with anticholinergic properties, including those dispensed acetylcholinesterase inhibitors. Further research is required to explore associations between different measures of anticholinergic exposure and clinically relevant outcomes in older people on a population level.

(PDF emailed within 0-6 h: $19.90)

Accession: 051578021

Download citation: RISBibTeXText

PMID: 23975730

DOI: 10.1007/s40266-013-0111-y


Related references

The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. Journal of Clinical Pharmacology 46(12): 1481-1486, 2006

Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs and Aging 30(5): 321-330, 2013

Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. American Journal of Geriatric Psychiatry 21(8): 785-793, 2014

Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs and Aging 30(2): 103-112, 2013

Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. American Journal of Geriatric PharmacoTherapy 4(1): 42-51, 2006

Audit of anticholinergic medication changes in older hospitalised patients using the Anticholinergic Drug Scale. Internal Medicine Journal 47(6): 689-694, 2017

Anticholinergic Risk and Frequency of Anticholinergic Drug Prescriptions in a Population Older Than 65. Journal of the American Medical Directors Association 17(3): 275.E1-4, 2016

Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs & Aging 30(2): 103-112, 2013

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. Bmc Geriatrics 15: 31, 2016

Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Therapeutic Advances in Drug Safety 4(6): 235-245, 2014

Anticholinergic and sedative drug burden in community-dwelling older people: a national database study. Bmj Open 8(7): E022500, 2018

Anticholinergic drug burden in older people's brain - how well is it measured?. Basic and Clinical Pharmacology and Toxicology 114(2): 151-159, 2014

Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. British Journal of Clinical Pharmacology 2018, 2018

Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdravstveno Varstvo 57(3): 140-147, 2018

Drug Burden Index score and anticholinergic risk scale as predictors of readmission to the hospital. Consultant Pharmacist 29(3): 158-168, 2014